Breaking News on Rare Disease Day — FDA Approves New Drug for Carcinoid Syndrome Diarrhea

On February 28, 2017, the US Food and Drug Administration (FDA) approved XERMELO™ (telotristat ethyl) 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy[i]. Read more from Lexicon Pharmaceuticals: http://www.lexpharma.com/

According to Lexicon, “Xermelo will be available by prescription, in a 250mg oral tablet, beginning on or about March 1. In an effort to ensure all appropriate patients have access to fast and affordable treatment, Lexicon has launched LexCares – a comprehensive program designed to guide patients through each step of their treatment journey. Through the LexCares Specialty Pharmacy, patients will have access to financial assistance programs that may reduce or eliminate out-of-pocket costs associated with their Xermelo prescription. For additional information, please visit www.xermelo.com/lexcares.
Print Friendly, PDF & Email